Analysts expect Abeona Therapeutics Inc (NASDAQ:ABEO) to post $1.21 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Abeona Therapeutics’ earnings. The lowest sales estimate is $500,000.00 and the highest is $2.40 million. Abeona Therapeutics posted sales of $2.60 million in the same quarter last year, which suggests a negative year-over-year growth rate of 53.5%. The business is expected to announce its next earnings report on Friday, May 10th.

On average, analysts expect that Abeona Therapeutics will report full year sales of $3.76 million for the current year, with estimates ranging from $2.88 million to $5.40 million. For the next fiscal year, analysts forecast that the company will post sales of $1.74 million, with estimates ranging from $220,000.00 to $3.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Abeona Therapeutics.

A number of research analysts recently commented on the company. Zacks Investment Research raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, March 20th. Cantor Fitzgerald set a $29.00 price target on Abeona Therapeutics and gave the stock a “buy” rating in a report on Tuesday, March 19th. ValuEngine raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 5th. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Abeona Therapeutics in a report on Thursday, February 21st. Finally, BidaskClub cut Abeona Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, February 12th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $26.00.

NASDAQ ABEO traded up $0.10 during trading hours on Thursday, reaching $7.27. The company’s stock had a trading volume of 220,147 shares, compared to its average volume of 395,499. Abeona Therapeutics has a 1 year low of $6.26 and a 1 year high of $22.00. The stock has a market cap of $358.18 million, a PE ratio of -6.11 and a beta of 1.93.

Institutional investors and hedge funds have recently modified their holdings of the company. Metropolitan Life Insurance Co. NY raised its holdings in shares of Abeona Therapeutics by 247.2% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 10,194 shares of the biopharmaceutical company’s stock worth $73,000 after acquiring an additional 7,258 shares in the last quarter. Parkside Advisors LLC raised its holdings in shares of Abeona Therapeutics by 16.0% during the 4th quarter. Parkside Advisors LLC now owns 14,530 shares of the biopharmaceutical company’s stock worth $104,000 after acquiring an additional 2,000 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in shares of Abeona Therapeutics by 178.9% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 18,237 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 11,698 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of Abeona Therapeutics by 23.7% during the 4th quarter. SG Americas Securities LLC now owns 22,720 shares of the biopharmaceutical company’s stock worth $162,000 after acquiring an additional 4,351 shares in the last quarter. Finally, Trexquant Investment LP purchased a new stake in shares of Abeona Therapeutics during the 3rd quarter worth approximately $163,000. 67.91% of the stock is currently owned by institutional investors and hedge funds.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Further Reading: The Structure of a Futures Contract

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.